38th week of 2013 patent applcation highlights part 58 |
Patent application number | Title | Published |
20130244987 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES - Provided herein are chemical matrices, compositions, methods and devices for the treatment of skin diseases and disorders in an individual. Described herein are non-homogenous chemical matrices and compositions comprising an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, optionally, at least one pharmaceutical agent, wherein the alcohol is distributed within the chemical matrix as a microbubble. Additionally, methods are described for the use of said chemical matrices and compositions for the treatment of skin diseases and disorders. | 2013-09-19 |
20130244988 | CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS - Compositions containing β | 2013-09-19 |
20130244990 | GENETIC POLYMORPHISMS ASSOCIATED WITH DEPRESSION - The present disclosure provides methods for determining risk for depression, as well as compositions for use in such methods. | 2013-09-19 |
20130244991 | USE OF 3-METHOXY-PREGNENOLONE FOR THE PREPARATION OF A DRUG FOR TREATING DEPRESSIVE DISORDERS AND LONG-TERM NEUROLOGICAL DISEASES - A method for the treatment of a traumatic brain lesion comprises administering to the patient an effective quantity of 3∃-methoxy-pregna-5-ene-20-one (3∃-methoxy-PREG). | 2013-09-19 |
20130244992 | Method of Inhibiting AB-Type Bacterial Toxins and Treatment for Associated Diseases - Disclosed herein are compounds useful in inhibiting the action of AB-type bacterial toxins such as cholera, traveler's diarrhea, enterohemorrhagic diarrhea caused by | 2013-09-19 |
20130244993 | SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE - The present invention relates to compounds defined by formula I: wherein the variables A | 2013-09-19 |
20130244994 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 - This invention relates to novel compounds of the Formula (I) | 2013-09-19 |
20130244995 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS - Compounds of general formula (I), their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, and methods of treating diseases with said compounds. | 2013-09-19 |
20130244996 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compounds of formula (I): | 2013-09-19 |
20130244997 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: | 2013-09-19 |
20130244998 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (I) as follows: | 2013-09-19 |
20130244999 | Substituted Heterocyclic Compounds - The present invention relates to substituted heterocyclic compounds of Formula I: | 2013-09-19 |
20130245000 | BICYCLIC GPR119 MODULATORS - The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods of treating, preventing and/or managing diseases, disorders syndromes or conditions associated with the modulation of GPR119 receptor by using either alone or in combinations of Formula (I). | 2013-09-19 |
20130245001 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE - The present invention relates to salts, hydrates, and polymorphs of bicyclic heteroaryl compounds, and pharmaceutical compositions thereof, which may be useful as inhibitors of H | 2013-09-19 |
20130245002 | Triazolopyridine Compounds - The invention relates to compounds of formula (I) and salts thereof: | 2013-09-19 |
20130245003 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS - The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. | 2013-09-19 |
20130245004 | ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME - Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs. | 2013-09-19 |
20130245005 | QUINOLIN-4 (1H) -ONE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES - Compounds of Formula (I): able to inhibit kinase activity, in particular Phosphatidylinositol 3-Kinases activity. The disclosure also relates to the use of compounds of Formula (I) for treatment of pathological conditions associated to alterations in Phosphatidylinositol 3-Kinases activity. | 2013-09-19 |
20130245006 | NOVEL INDOLIZINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF - The invention relates to indolizine derivatives of general formula (I), where A, B, m, W, n and R2 are as defined in claim | 2013-09-19 |
20130245007 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS - The present invention relates to new 2-piperazin-1-yl-4H-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections caused by bacteria, especially diseases like tuberculosis (TB), Buruli ulcer and leprosy that result from infection with closely related mycobacteria. (I). | 2013-09-19 |
20130245008 | NITROBENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATIONS THEREOF - The invention relates to the nitrobenzothiazole derivatives of general formula (I): and to the use thereof for treating tuberculosis. | 2013-09-19 |
20130245009 | NOVEL COMPOUNDS - The present invention relates to new CGRP-antagonists of general formulae Ia and Ib | 2013-09-19 |
20130245010 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 2013-09-19 |
20130245011 | Modulators of ATP-Binding Cassette Transporters - Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 2013-09-19 |
20130245012 | 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS - Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders. | 2013-09-19 |
20130245013 | STORAGE STABLE PERFUSION SOLUTION FOR DIHYDROPTERIDINONES - Disclosed are storage stable aqueous infusible or injectable solutions containing an active substance of general formula (I) | 2013-09-19 |
20130245014 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF - Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 2013-09-19 |
20130245015 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS - Compounds having the formula | 2013-09-19 |
20130245016 | INDOLES - Herein are disclosed indoles of formula (I) | 2013-09-19 |
20130245017 | CRYSTALLINE FORM OF RIVAROXABAN DIHYDRATE - The present invention relates to a novel crystalline dihydrate of Rivaroxaban, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline dehydrate and to processes for preparing and storing said pharmaceutical compositions. The invention also relates to a crystalline formic acid solvate of Rivaroxaban, processes for the preparation of crystalline Rivaroxaban formic acid solvate and to the use of said Rivaroxaban formic acid solvate in the manufacture of the crystalline dihydrate of Rivaroxaban. | 2013-09-19 |
20130245018 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc. | 2013-09-19 |
20130245019 | ACRYLOMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION - Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R′, R″, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them. | 2013-09-19 |
20130245020 | SYNERGISTIC ANTIMICROBIAL COMPOSITION - A synergistic antimicrobial composition. The composition contains at least two components. The first component is ortho-phenylphenol or its alkali metal or ammonium salts. The second component is 4,4-dimethyloxazolidine (DMOZ). | 2013-09-19 |
20130245021 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE - Imidazo[1,2-b]pyridazine-based compounds of the formula: | 2013-09-19 |
20130245022 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE - Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis). | 2013-09-19 |
20130245023 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF - The invention relates to the 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine derivatives corresponding to general formula (I): | 2013-09-19 |
20130245024 | Combination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity - The present invention relates to pharmaceutical compositions and methods for the treatment of diabetes, obesity or disorders related to diabetes or obesity. The compositions comprise a combination of a particular PPARγ agonist and a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor. The methods include the administration of the combination of a particular PPARγ agonist and a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor. | 2013-09-19 |
20130245025 | Compounds that modulate intracellular calcium - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. | 2013-09-19 |
20130245026 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS - Provided herein are methods for treating or preventing head and neck squamous cell carcinoma, comprising administering an effective amount of a TOR kinase inhibitor to a patient having head and neck squamous cell carcinoma. | 2013-09-19 |
20130245027 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS - Provided herein are methods for treating or preventing triple negative breast cancer or hormone receptor positive breast cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having triple negative breast cancer or hormone receptor positive breast cancer. | 2013-09-19 |
20130245028 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS - Provided herein are methods for treating or preventing ETS overexpressing castration-resistant prostate cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having ETS overexpressing castration-resistant prostate cancer. | 2013-09-19 |
20130245029 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS - Provided herein are methods for treating or preventing ETS overexpressing Ewings sarcoma, comprising administering an effective amount of a TOR kinase inhibitor to a patient having ETS overexpressing Ewings sarcoma. | 2013-09-19 |
20130245030 | PREPARATIONS AND METHODS FOR AMELIORATING OR REDUCING PRESBYOPIA - This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation. | 2013-09-19 |
20130245031 | FUSED HETEROAROMATIC PYRROLIDINONES - Disclosed are compounds of Formula 1, | 2013-09-19 |
20130245032 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS OF THEIR USE - According to the embodiments described herein, a tricyclic SUMOylation inhibitor compound is provided. In some embodiments, a method for inhibiting a SUMOylation enzyme in a cell is provided. Such a method may include administering a SUMOylation inhibitor compound to the cell. In some aspects, the SUMOylation enzyme is SUMO E1 or SUMO E2. In some aspects, the method may be used to inhibit a cancer cell in vitro (e.g., grown in culture) or in vivo (e.g., as part of a tumor in a subject). In other embodiments, a method for treating a cancer, degenerative diseases and viral infection is provided. Such a method may include administering an effective amount of a pharmaceutical composition to a subject having the cancer. The pharmaceutical composition may include a SUMOylation inhibitor compound. In some embodiments, the method for treating a disease may further comprise administering one or more DNA-damaging therapy in combination with administration of the pharmaceutical composition. | 2013-09-19 |
20130245033 | AMIDE COMPOUNDS - A compound represented by formula (I) and the pharmaceutical acceptable salt thereof are disclosed, | 2013-09-19 |
20130245034 | Inhibitors Of Histone Deacetylase - This invention comprises the novel compounds of formula (I) | 2013-09-19 |
20130245035 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS - Described are a series of 2-pyridone compounds as a potent and selective new class of type II topoisomerase inhibitors with broad-spectrum antimicrobial activity having the general formula (I); where R1, R2, X, and Y are defined herein Such compounds can be used in methods for treating an infection caused by a gram-positive pathogen, a gram-negative pathogen, or a drug-resistant strains thereof. | 2013-09-19 |
20130245036 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION - A crystalline form of (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, which is useful in the treatment of a disease or disorder associated with the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively. | 2013-09-19 |
20130245037 | Stabilization of Hypoxia Inducible Factor (HIF) Alpha - The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided. | 2013-09-19 |
20130245038 | Method For Selecting Or Identifying A Subject For V1B Antagonist Therapy - Provided herein is a method for detecting an HPA axis function marker in a biological sample. The method may be used to determine whether a patient is a suitable candidate for treatment with a V | 2013-09-19 |
20130245039 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS - Treatment of proliferative diseases with a combination of a b-Raf inhibitor and MDM2 inhibitor. | 2013-09-19 |
20130245040 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS - The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-HI's, function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-HI's bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein. | 2013-09-19 |
20130245041 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS - In one aspect, the invention relates to compounds having the formula: | 2013-09-19 |
20130245042 | Positive Allosteric Modulators of MGLUR2 - The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system. | 2013-09-19 |
20130245043 | SUBSTITUTED IMIDAZOPYRIMIDIN-5(6H)-ONES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS - In one aspect, the invention relates to imidazopyrimidin-5(6H)-one analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2013-09-19 |
20130245044 | TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS - Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning. | 2013-09-19 |
20130245045 | SELECTIVE PHOSPHODIESTERASE 9A INHIBITORS AS MEDICAMENTS FOR IMPROVING COGNITIVE PROCESSES - The invention relates to the use of selective phosphodiesterase 9A (PDE9A) inhibitors for producing medicaments for improving perception, concentration, cognitive processes, learning and/or memory. | 2013-09-19 |
20130245046 | NOVEL 2-ALKYNYL-N9-PROPARGYLADENINE AND MEDICINAL USE THEREOF - In the present invention, a novel 2-alkynyl-N9-propargyladenine represented by formula (I) | 2013-09-19 |
20130245047 | COMPOSITIONS FOR TREATING CANCER-RELATED FATIGUE AND METHODS OF SCREENING THEREOF - An animal model has been developed based the understanding that a central mechanism in patients with CTRF is that chemotherapy and/or radiation initiates canonical pathways leading to the development of disrupted sleep architecture, resulting in disruption of REM sleep and fatigue and cognitive dysfunction. Drugs that restore the activity patterns and levels towards normal and/or decrease the pro-inflammatory cytokines associated with the disrupted sleep, should be effective in alleviating one or more symptoms of CTRF. Pentoxifylline was demonstrated to improve activity levels in animals treated with etoposide. | 2013-09-19 |
20130245048 | 4-AZA-2, 3-DIDEHYDROPODOPHYLLOTOXIN COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF - The present invention provides 4-Aza-2,3-didehydropodophyllotoxin compound of general formula A (4a-4z and 4aa-4ae) as useful potential antitumour agents against human cancer cell lines. The present invention further provides a process for the synthesis of 4-Aza-2,3-didehydropodophyllotoxin compounds (4a-4z and 4aa-4ae). | 2013-09-19 |
20130245049 | Novel Antiviral Compounds - The present invention relates to compounds of formula (A), as further defined herein, having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. The invention further relates to the use of such compounds, optionally combined with one or more other drugs having antiviral activity, for the treatment of animals suffering from viral infections, in particular HIV infection. | 2013-09-19 |
20130245050 | Use of N-Phenylethylpyraozole Carboxamide Derivatives or Salts Thereof for Extending Shelf Life of Fruits and Vegetables - The present invention relates to the use of N-phenylethylpyrazole carboxamide derivatives or salts thereof for extended shelf life and storage stability of fruits and vegetables, to a method for extending shelf life or fruits and vegetables by applying N-phenylethylpyrazole carboxamide derivatives or salts thereof to the crops prior to the harvest of the fruits or vegetables. | 2013-09-19 |
20130245051 | CYCLIC UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 - This invention relates to novel compounds of the Formula (I), (Ia) and (Ib), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, j which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell Or the inhibition of the conversion of cortisone to Cortisol in a cell. | 2013-09-19 |
20130245052 | NOVEL POLYMORPH OF NILOTINIB HYDROCHLORIDE - The present invention provides a novel crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical compositions comprising it. | 2013-09-19 |
20130245053 | Pesticidal Compositions - The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations. | 2013-09-19 |
20130245054 | USE OF BINDERS FOR MANUFACTURING STORAGE STABLE FORMULATIONS - The present invention relates to storage stable prolonged release pharmaceutical dosage forms comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof, the manufacture thereof as well as their use for administration to human beings. | 2013-09-19 |
20130245055 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2013-09-19 |
20130245056 | INCREASING DRUG BIOAVAILABILITY IN NALTREXONE THERAPY - Disclosed are compositions, uses, methods and kits for increasing drug bioavailability in a naltrexone therapy. | 2013-09-19 |
20130245057 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING SYMPTOMS OF HORMONAL VARIATIONS - The present invention relates to methods, compositions, and kits for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of Dextromethorphan or Dextrorphan, or a pharmaceutically acceptable salt thereof, to a subject having one or more symptoms of hormonal variations. | 2013-09-19 |
20130245058 | MEDICAL PRODUCT WITH A PARTICLE-FREE COATING RELEASING AN ACTIVE SUBSTANCE - Embodiments described herein concern medical products, which come into contact with the organism, such as short-term implants and long-term implants, coated with at least one layer, containing a molecular-disperse distributed or dissolved active substance in at least one carrier and optionally one or more adjuvants, wherein the at least one layer forms a stably spreadable solution, methods for making this coating of stably spreadable solution and use of the medical products coated with the stably spreadable solution. | 2013-09-19 |
20130245060 | NOVEL COMPOSITION - This invention relates to topical pharmaceutical compositions comprising the active agent 4-methyl-1-(2-phenylethyl)-8-phenoxy-2,3-dihydro-1H-pyrrolo[3,2-c]-quinoline or a pharmaceutically acceptable derivative thereof and a hydrophobic excipient, to a process for preparing such compositions, and to the use of such compositions for the treatment of microbial infections. | 2013-09-19 |
20130245061 | PHARMACEUTICAL COMPOSITIONS - A pharmaceutical composition for the oral administration of a therapeutic compound of formula (I), comprising granules that comprise at least therapeutic compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof; at least one non-ionic surfactant that is Vitamin E-TPGS in an amount ranging from about 15 to about 80% by weight of the composition; and at least one a dissolution enhancing agent selected from polyethylene glycol, polyethylene oxide, and any combination of the foregoing; processes for making such pharmaceutical compositions; a kit comprising such pharmaceutical composition and the instructions for administration thereof; and related uses and methods of treatment. | 2013-09-19 |
20130245062 | NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS - Disclosed are nitrile derivatives and pharmaceutical compositions comprising nitrile derivatives. The pharmaceutical compositions comprise compounds of the formula I | 2013-09-19 |
20130245063 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. | 2013-09-19 |
20130245064 | NOVEL NEUROTRYPSIN INHIBITORS - The invention relates to novel acylamino-hydroxy-benzamides of formula (I), wherein R | 2013-09-19 |
20130245065 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM - The present invention relates to processes for the preparation of quinoline-3-carboxamide derivatives, such as sodium 5-chloro-3-(ethylphenylcarbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate (Laquinimod sodium). The present invention further relates to intermediates formed in such processes. | 2013-09-19 |
20130245066 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors - 2-pyridyl-substituted imidazoles which are used advantageously in the treatment of diseases mediated by ALK 5 or ALK 4 receptor or both. | 2013-09-19 |
20130245067 | DEUTERIUM-ENRICHED LENALIDOMIDE - The present application describes deuterium-enriched lenalidomide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2013-09-19 |
20130245068 | COMPOSITION COMPRISING BENPROPERINE DERIVATIVES AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING ANGIOGENESIS-RELATED DISEASES - The present invention relates to a novel pharmaceutical composition of benproperine derivatives for preventing and treating angiogenesis-related diseases. The benproperine derivatives and pharmaceutically acceptable salts thereof according to the present invention inhibit cancer cell migration and the angiogenesis of vascular endothelial cells, and therefore can be effectively used not only as an anticancer agent, but also as an agent for preventing and treating diseases caused by abnormal angiogenesis, such as diabetic retinopathy and corneal transplant rejection. | 2013-09-19 |
20130245069 | FORMULATIONS AND METHODS FOR LYOPHILIZATION AND LYOPHILATES PROVIDED THEREBY - The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided. | 2013-09-19 |
20130245070 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME - The present invention relates to a method for enhancing arginase activity in a damaged or injured cell. In other aspects, the invention provides a method for treating a disorder that can be treated by enhancing arginase activity in a human in need thereof, the method comprising administering to the human an effective amount of a compound that enhances arginase activity. Such disorders include ischemia, hypoxia, neurodegenerative disease or condition, stroke or trauma of the nervous system. In yet another aspect, the invention provides methods for promoting regeneration of a neural cell in a human in need thereof. | 2013-09-19 |
20130245071 | MULTIPLE PPI DOSAGE FORM - Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml. | 2013-09-19 |
20130245072 | INSECTICIDAL COMPOUNDS - A compound of formula (I): | 2013-09-19 |
20130245073 | GEL CONTAINING PIRFENIDONE - The invention relates to a gel composition containing pirfenidone, which is advantageous over other cutaneously administered pharmaceutical forms known in the prior art and which can be used in treatment for the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions. | 2013-09-19 |
20130245074 | NOVEL COMPOUND AND MEDICAL USE THEREOF - Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa. | 2013-09-19 |
20130245075 | MELANOGENESIS INHIBITION-METHODS AND COMPOSITIONS THEREOF - The present invention relates to melanogenesis inhibition using an effective amount of piper longumine obtained from the roots of | 2013-09-19 |
20130245076 | PROLYL HYDROXYLASE INHIBITORS AND METHOD OF USE - The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. | 2013-09-19 |
20130245077 | CRYSTALLINE FORMS OF FEBUXOSTAT - New forms of Febuxostat have bean, prepared and characterized. These forms are useful for examples in the chronic management of hyperuricemia in patients with gout. | 2013-09-19 |
20130245078 | SALT COMPOUND - A salt compound, and methods for mitigating neurodegeneration, effecting neuroprotection and/or effecting cognition enhancement in a subject using the salt compound are described. Neurological or cognitive conditions are treated by administering to a subject an effective amount of a therapeutic salt compound comprising a nitrate ester. | 2013-09-19 |
20130245079 | Use of polyhexamethylene guanidine hydrochloride as preservative for preventing and controlling citrus sour rot and its application - The use of polyhexamethylene guanidine hydrochloride as preservative for preventing and controlling citrus sour rot and its application are disclosed by the present invention. The citrus preservative calculated by 100% total mass fraction comprises 0.05%-0.5% polyhexamethylene guanidine hydrochloride, 0.05%-0.2% of one or more selected from the group consisting of a mixture of several of the following: 0.05%-0.2% imidazole fungicidebactericide, benzimidazole fungicidebactericide, pyrimethanil, fludioxonil and [or] azoxystrobin, and 0.02%-0.15% polyethenoxy ether emulsion or quaternary ammonium salt emulsion, and the rest is water. The citrus preservative can significantly inhibit the decay of citrus fruit such as Citrus microcarpa during storage, especially the incidence of sour rot. So the commercial value of citrus is obviously increased. | 2013-09-19 |
20130245080 | BENZOTHIAZOLONE COMPOUND - The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form | 2013-09-19 |
20130245081 | Compositions and Methods for Treating Amyotrophic Lateral Sclerosis - Pharmaceutical compositions of dexpramipexole and methods of using such compositions for the treatment of ALS are disclosed. | 2013-09-19 |
20130245082 | BIOAVAILABLE COMPOSITIONS OF METAXOLONE COMPRISING NONVOLATILE LIQUIDS AND PROCESSES FOR PRODUCING THE SAME - Pharmaceutical compositions comprising metaxalone which demonstrate improved dissolution and bioavailability characteristics compared to the commercially available product, and methods of producing them are provided. In a preferred embodiment, a dosage form comprising metaxalone and at least one inactive powder excipient is bioequivalent to its commercially available counterpart (Skelaxin® 400-mg tablets) after oral administration to fasting or non-fasting human subjects, while at the same time displaying faster drug dissolution rates than the Skelaxin® tablets as demonstrated from three different dissolution tests. In another preferred embodiment, a dosage form comprising metaxalone, at least one inactive powder excipient and a nonvolatile liquid is significantly more bioavailable than the commercially available Skelaxin® 400-mg tablets after oral administration to fasting human subjects. | 2013-09-19 |
20130245083 | METHODS OF TREATMENT WITH BIOAVAILABLE COMPOSITIONS OF METAXALONE COMPRISING NONVOLATILE LIQUIDS - Pharmaceutical compositions comprising metaxalone which demonstrate improved dissolution and bioavailability characteristics compared to the commercially available product, and methods of producing them are provided. In a preferred embodiment, a dosage form comprising metaxalone and at least one inactive powder excipient is bioequivalent to its commercially available counterpart (Skelaxin® 400-mg tablets) after oral administration to fasting or non-fasting human subjects, while at the same time displaying faster drug dissolution rates than the Skelaxin® tablets as demonstrated from three different dissolution tests. In another preferred embodiment, a dosage form comprising metaxalone, at least one inactive powder excipient and a nonvolatile liquid is significantly more bioavailable than the commercially available Skelaxin® 400-mg tablets after oral administration to fasting human subjects. | 2013-09-19 |
20130245084 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS - Compounds of general formula (I) their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, and methods of treating diseases with said compounds. | 2013-09-19 |
20130245085 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: | 2013-09-19 |
20130245086 | Novel Solid Forms Of Bendamustine Hydrochloride - Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use. | 2013-09-19 |
20130245087 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS - The invention is directed to compounds having the formula: | 2013-09-19 |
20130245088 | KETOROLAC COMPOSITIONS FOR CORNEAL WOUND HEALING - The present invention is directed to an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose which promotes epithelial wound healing in a patients cornea. | 2013-09-19 |